Skip to main content
    C

    Context Therapeutics Inc (CNTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.17
    +0.01 (+3.07%)

    Market Cap: $15.24M

    Last updated: Nov 17, 2026 at 4:41 PM ET

    Context Therapeutics Inc (CNTX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Context Therapeutics (CNTX) has a market cap of $15.24M. It holds $34.41M more cash than debt, 225.75% of its market cap.

    Total Valuation

    Market Cap$15.24M
    Latest price (Nov 17, 2026)$0.17

    Key Dates

    The next earnings report is expected on Mar 22, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 22, 2027 (expected)
    Last Earnings DateNov 10, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count held steady in the quarter ended Sep 30, 2026 and grew 8.75% a year over 2 years.

    Shares Outstanding95.18M
    Shares Change (YoY)0.00%
    Shares Change (QoQ)0.00%
    Share Count Growth (2Y CAGR)+8.75%

    Price Statistics

    The stock is down 85.26% over 52 weeks and trades 39.29% below its 50-day average.

    Beta (1Y)0.38
    52-Week Change-85.26%
    1-Month Change-28.27%
    3-Month Change-64.92%
    6-Month Change-92.12%
    5-Year Change-96.72%
    Total Return (1Y)-85.26%
    Total Return (3Y CAGR)-44.49%
    Total Return (5Y CAGR)-47.91%
    Max Drawdown (1Y)-95.06%
    Max Drawdown (3Y)-95.06%
    Sharpe Ratio (1Y)-1.57
    Correlation with SPY (1Y)0.04
    50-Day Average$0.28
    200-Day Average$1.35
    52-Week Range$0.16 to $3.62
    RSI (14 Days)33.6
    Average Volume (20 Days)1.64M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 6.59x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio6.59x
    Quick Ratio6.59x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -141.55% over the last 12 months, against a 5-year average of -70.80%.

    Return on Equity (ROE)-141.55%
    Return on Assets (ROA)-120.12%
    ROE (5Y Average)-70.80%
    ROA (5Y Average)-57.73%
    ROIC (5Y Average)-51.60%

    Scores

    CNTX has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Gross Profit-$32.28K
    Operating Income-$46.08M
    Pretax Income-$43.89M
    Net Income-$43.89M
    Reported EPS (TTM)-$0.46

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 84.87% of the $36.54M in total assets.

    Cash and Equivalents$34.41M
    Total Debt$0
    Net Cash$34.41M
    Net Cash Per Share$0.36
    Working Capital$30.77M
    Shareholder Equity$31.01M
    Book Value Per Share$0.33
    Total Assets$36.54M
    Total Liabilities$5.53M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$33.97M
    FCF Per Share-$0.37
    Depreciation and Amortization$132.98K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Growth

    Book Value Per Share Growth (2Y CAGR)-5.91%
    Tangible Book Per Share Growth (2Y CAGR)-5.91%

    Revenue and profit by year

    Dividends and Yields

    CNTX does not pay a dividend.

    Buyback Yield0.00%
    Shareholder Yield0.00%

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About CNTX

    What is CNTX's market cap?

    Context Therapeutics has a market cap of $15.24M.

    How many shares of CNTX are outstanding?

    Context Therapeutics has 95.18M shares outstanding. The count is up 0.00% from a year earlier.

    Does CNTX pay a dividend?

    No. Context Therapeutics does not pay a dividend.

    How much debt does CNTX have?

    Context Therapeutics has $0 of total debt and $34.41M of cash and equivalents, a net cash position of $34.41M.